

# Analysis of trends in prevalence, awareness, treatment and control of high blood pressure in Portugal: Examples of successful interventions against hypertension

Massimo Volpe, MD <sup>1,2</sup>, Giuliano Tocci, MD, PhD <sup>1</sup>.

<sup>1</sup> Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.

<sup>2</sup> IRCCS Neuromed, Pozzilli (IS), Italy.

Received for publication: Jan 22, 2017

Accepted in revised form: Feb 02, 2017

**Key words:** hypertension prevalence; hypertension treatment; blood pressure; coronary artery disease; stroke; cardiovascular prevention.

Essential hypertension is currently the major driver for cardiovascular (CV) morbidity and mortality worldwide. Indeed, high blood pressure (BP) levels are strongly and independently related to high risk of major CV events, including coronary artery disease, stroke, congestive heart failure and renal disease, compared to normotension<sup>1,2</sup>, while solid evidence demonstrates that BP reductions below the recommended targets of 140/90 mmHg reduce the risk of developing hypertension-related complications and improve event-free survival in treated hypertensive patients at high or very high CV risk<sup>3-7</sup>.

In view of the progressive ageing of the population, the large prevalence of the disease in adult and, mostly, elderly individuals, as well as in view of the mounting socio-economic impact and the potentially life-threatening consequences of uncontrolled BP, closer attention has been paid to this condition, in order to plan educational and therapeutic campaigns aimed at improving awareness and ameliorating treatment and control at national and local levels. For these purposes, several reports on hypertension prevalence, awareness, treatment and control have been made available in the United States<sup>8</sup>, China<sup>9</sup>, Italy<sup>10</sup>, Portugal<sup>11</sup> and in many other countries<sup>12</sup> over the last two decades. These surveys appear to be very useful, since

they permit repeated and comparable cross-sectional analyses, estimation of the disease burden for health-care systems, and evaluation of the effectiveness of educational interventions and therapeutic actions aimed at improving patients' awareness and physicians' clinical management of hypertension in different time periods.

As an example, in Italy we were able to show relatively poor BP control rates among treated hypertensive patients included in a systematic analysis of observational studies performed in real-life practice<sup>13</sup>. At a national level, a trend toward improvement in BP control was observed in a subsequent analysis of a large sample of hypertensive outpatients, mostly followed by general practitioners<sup>14</sup>. Following these observations, several calls-to-action and educational interventions were proposed to improve hypertension management and control with the aim of achieving 70% of patients within BP target values by 2015<sup>15</sup>. Such an objective appeared to be feasible both on the basis of BP control rates achieved in large randomized controlled trials performed in the setting of general practice<sup>16,17</sup>, and on the basis of data generated in other national campaigns<sup>18-21</sup>. Indeed, two recent independent ad interim analyses have reported very promising results, reporting that

BP control rates rose to 60% of treated hypertensive patients.

As observed in the Italian experience, a recent analysis showed similar positive trends in hypertension awareness and control in a representative sample of adult individuals in Portugal (Figure 1)<sup>22</sup>. In this population-based cross-sectional survey, hypertension was recorded in about 44% of the overall population sample and BP control was achieved in about 57% of treated hypertensive patients. The study has several strengths and potential clinical implications. First of all, it includes a predominant proportion (52%) of women, which have been traditionally under-represented in this kind of epidemiological analysis on hypertension<sup>22</sup>. Secondly, it incorporates in the study protocol the systematic assessment of 24-hour urine sodium and potassium excretions and their correlations with BP levels and control, thus showing that 24-hour urinary sodium was higher in patients with hypertension than in those with normotension (185.4±64.8 vs. 177.8±64.5 mmol/day; P<0.02), without significant differences between controlled and uncontrolled hypertensive patients<sup>22</sup>. Finally, despite a similar prevalence of hypertension, it shows a marked and significant increase in high BP awareness, treatment and control not only compared with previous analysis performed in 2003, but also between baseline (visit 1) and final (visit 2) observations performed during a limited time frame (10-15 day)<sup>22</sup>.

This implies that the simple inclusion in an observational study protocol might improve physicians' attention and patients' awareness with regard to the clinical management of hypertension and ameliorate the overall rates of BP control, as previously observed<sup>23</sup>.

As expected, this study protocol has some intrinsic limitations that should be considered, mostly including the descriptive nature of the survey; the relatively limited sample size not fully representative of the whole national population; the different methodologies applied for measuring BP levels during the different time periods. Despite these aspects, however, these observations confirmed that BP control rates can be improved with respect to those reported in previous surveys<sup>11</sup>, as well as in other analyses made available in the country<sup>24</sup>, thus confirming a favourable positive trend in the rates of BP control achieved in Portugal and in other countries over the last few years<sup>25</sup>.


**Disclosure of potential conflicts of interest:** none declared.

## References

1. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362(9395):1527-35.
2. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005;165(12):1410-9.

**Figure 1**

Prevalence, awareness, treatment and control of hypertension reported in two subsequent analyses performed in Portugal and Italy, respectively. Data are derived from the following references: Portugal, 2003<sup>11</sup>; Portugal, 2013<sup>22</sup>; Italy, 2003<sup>26</sup>; Italy, 2013<sup>27</sup>.



3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359(9311):995-1003.
4. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359(9311):1004-10.
5. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005;366(9489):895-906.
6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004;363(9426):2022-31.
7. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. *JAMA*. 2000;283(15):1967-75.
8. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *JAMA*. 2010 May 26;303(20):2043-50.
9. Wu L, He Y, Jiang B, Sun D, Wang J, Liu M, et al. Trends in prevalence, awareness, treatment and control of hypertension during 2001-2010 in an urban elderly population of China. *PLoS one*. 2015;10(8):e0132814.
10. Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, Ferri C, Virdis A, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded From 2004 to 2014 during world hypertension day in Italy. *J Clin Hypertens (Greenwich)*. 2016;18(6):551-6.
11. Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. *J Hypertens*. 2005;23(9):1661-6.
12. Antikainen RL, Moltchanov VA, Chukwuma C, Sr., Kuulasmaa KA, Marques-Vidal PM, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. *Eur J Cardiovasc Prev Rehabil*. 2006;13(1):13-29.
13. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. *J Hypertens*. 2007;25(7):1491-8.
14. Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. *J Hypertens*. 2012;30(6):1065-74.
15. Volpe M. The changing role of hypertension societies: shifting gears in Italy. *High Blood Press Cardiovasc Prev*. 2012;19(1):1-2.
16. Officers A, Coordinators for the ACRGTA, Lipid-lowering treatment to prevent heart attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288(23):2981-97.
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med*. 2003 Jan 30;348(5):383-93.
18. Mohan S, Campbell NR. Hypertension management: time to shift gears and scale up national efforts. *Hypertension*. 2009;53(3):450-1.
19. Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. *Hypertension*. 2009;53(2):128-34.
20. Falaschetti E, Campbell NR, Mohan S, Poulter N. Implementation of pay for performance policy in England. *Hypertension*. 2009;54(1):e5.
21. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. *Hypertension*. 2009;53(4):646-53.
22. Polonia J, Martins L, Pinto F, Nazare J. Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study. *J Hypertens*. 2014;32(6):1211-21.
23. Volpe M, Rosei EA, Ambrosioni E, Leonetti G, Trimarco B, Mancia G. Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. *J Hypertens*. 2007;25(12):2390-7.
24. Vinhas J, Gardete-Correia L, Boavida JM, Raposo JF, Mesquita A, Fona MC, et al. Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study. *Nephron Clin Pract*. 2011;119(1):c35-40.
25. Mirzaei M, Truswell AS, Arnett K, Page A, Taylor R, Leeder SR. Cerebrovascular disease in 48 countries: secular trends in mortality 1950-2005. *J Neurol Neurosurg Psychiatry*. 2012;83(2):138-45.
26. Filippi A, Paolini I, Innocenti F, Mazzaglia G, Battaglia A, Brignoli O. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice. *J Hum Hypertens*. 2009;23(11):758-63.
27. Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. *J Hum Hypertens*. Advance online publication 15 September 2016.

#### Correspondence to:

Prof. Massimo Volpe, MD  
 Chair and Division of Cardiology  
 Department of Clinical and Molecular Medicine  
 Faculty of Medicine and Psychology  
 University of Rome Sapienza  
 Sant'Andrea Hospital, Rome, Italy  
 Phone: +39 06 3377 5654  
 Fax: +39 06 3377 6323  
 E-mail: massimo.volpe@uniroma1.it